MA47392A1 - Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques - Google Patents

Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques

Info

Publication number
MA47392A1
MA47392A1 MA47392A MA47392A MA47392A1 MA 47392 A1 MA47392 A1 MA 47392A1 MA 47392 A MA47392 A MA 47392A MA 47392 A MA47392 A MA 47392A MA 47392 A1 MA47392 A1 MA 47392A1
Authority
MA
Morocco
Prior art keywords
bis
protein conjugates
octahydrophenanthrene
carboxamides
octahydrophenanthrene carboxamides
Prior art date
Application number
MA47392A
Other languages
English (en)
Other versions
MA47392B1 (fr
Inventor
Andrew J Murphy
William Olson
Amy Han
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62245504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA47392(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA47392A1 publication Critical patent/MA47392A1/fr
Publication of MA47392B1 publication Critical patent/MA47392B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes pour le traitement de maladies et de troubles associés au récepteur hépatique x, notamment les bis-octahydrophénanthrène carboxamides et les conjugués protéiques de médicaments (par exemple, anticorps) de ceux-ci.
MA47392A 2017-05-18 2018-05-09 Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques MA47392B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508327P 2017-05-18 2017-05-18
PCT/US2018/031910 WO2018213082A1 (fr) 2017-05-18 2018-05-09 Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques

Publications (2)

Publication Number Publication Date
MA47392A1 true MA47392A1 (fr) 2020-10-28
MA47392B1 MA47392B1 (fr) 2021-09-30

Family

ID=62245504

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47392A MA47392B1 (fr) 2017-05-18 2018-05-09 Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques

Country Status (16)

Country Link
US (2) US20180334426A1 (fr)
EP (1) EP3625209A1 (fr)
JP (2) JP2020520926A (fr)
KR (1) KR20200008579A (fr)
CN (1) CN111065622A (fr)
AU (1) AU2018269568B2 (fr)
BR (1) BR112019023990A2 (fr)
CA (1) CA3063872A1 (fr)
CL (1) CL2019003270A1 (fr)
CO (1) CO2019014286A2 (fr)
EA (1) EA201900562A1 (fr)
IL (1) IL270595B2 (fr)
MA (1) MA47392B1 (fr)
MX (1) MX2019013693A (fr)
PH (1) PH12019502576A1 (fr)
WO (1) WO2018213082A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202104259RA (en) 2016-11-08 2021-06-29 Regeneron Pharma Steroids and protein-conjugates thereof
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
EP3790899A1 (fr) 2018-05-09 2021-03-17 Regeneron Pharmaceuticals, Inc. Anticorps anti-msr1 et leurs procédés d'utilisation
EA202091135A1 (ru) * 2018-05-09 2020-10-14 Регенерон Фармасьютикалз, Инк. Гидрофильные линкеры для конъюгатов антитело-лекарственное средство
MX2021005822A (es) 2018-11-20 2021-07-15 Regeneron Pharma Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteinas de los mismos para usarse como agonistas de lxr.
EP3908323A2 (fr) * 2019-01-08 2021-11-17 Regeneron Pharmaceuticals, Inc. Lieurs sans trace et conjugués protéiques associés
JP2023521885A (ja) 2020-04-16 2023-05-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ディールス－アルダーコンジュゲーション方法
WO2021260232A1 (fr) * 2020-06-26 2021-12-30 Synaffix B.V. Procédés pour la préparation de constructions de charge utile de lieur
MX2023004935A (es) 2020-11-10 2023-07-07 Regeneron Pharma Conjugados de anticuerpos y selenio.
CN112661783B (zh) * 2020-12-28 2022-06-07 中国林业科学研究院林产化学工业研究所 一种硅氧烷二元松香基苯并环丁烯单体及其制备方法和应用
CN115006390B (zh) * 2022-06-27 2024-04-19 国药集团动物保健股份有限公司 一种病毒减毒制剂、其制备方法以及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JP2003516327A (ja) * 1999-12-13 2003-05-13 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化の予防および／または治療方法
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US6908934B2 (en) * 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
CA2568857A1 (fr) * 2004-06-24 2006-01-05 Galapagos N.V. Procedes et compositions permettant de favoriser l'homeostasie osseuse
US7238791B1 (en) * 2005-12-16 2007-07-03 Roche Diagnostics Operations, Inc. 6-monoacetylmorphine derivatives useful in immunoassay
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
DK2167963T3 (da) 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
US20110256157A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EA201390575A1 (ru) 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
CA2837167A1 (fr) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions contenant des derives de dolastatine lies a des acides amines non naturel
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
EP3309162A1 (fr) 2011-10-14 2018-04-18 Seattle Genetics, Inc. Conjugues cibles des pyrrolobenzodiazepines
EP2751111B1 (fr) 2011-10-14 2017-04-26 MedImmune Limited Dérivés asymmetriques de bis-(5H-pyrrolo[2,1-c][1,4]benzodiazépin-5-one) pour le traitement de maladies prolifératives ou auto-immunes
CA2850096C (fr) 2011-10-14 2018-07-03 Spirogen Sarl Procede de synthese et intermediaires pouvant servir a preparer des pyrrolobenzodiazepines
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
ES2659270T3 (es) 2012-10-23 2018-03-14 Synaffix B.V. Anticuerpo modificado, conjugado de anticuerpo y proceso de preparación de los mismos
ES2741308T3 (es) * 2013-10-15 2020-02-10 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20160324981A1 (en) * 2015-05-08 2016-11-10 The California Institute For Biomedical Research Liver x receptor agonists and uses thereof
EP3419670A2 (fr) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Conjugaison optimisée d'anticorps spécifique d'un site de transglutaminase
EP3790899A1 (fr) * 2018-05-09 2021-03-17 Regeneron Pharmaceuticals, Inc. Anticorps anti-msr1 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
KR20200008579A (ko) 2020-01-28
EP3625209A1 (fr) 2020-03-25
IL270595B2 (en) 2023-09-01
JP2023113639A (ja) 2023-08-16
PH12019502576A1 (en) 2020-09-28
WO2018213082A1 (fr) 2018-11-22
IL270595B1 (en) 2023-05-01
EA201900562A1 (ru) 2020-05-12
AU2018269568A1 (en) 2020-01-16
JP2020520926A (ja) 2020-07-16
BR112019023990A2 (pt) 2020-06-16
CN111065622A (zh) 2020-04-24
CO2019014286A2 (es) 2020-04-01
MX2019013693A (es) 2020-01-27
US20220112158A1 (en) 2022-04-14
IL270595A (fr) 2019-12-31
MA47392B1 (fr) 2021-09-30
AU2018269568B2 (en) 2022-03-24
US20180334426A1 (en) 2018-11-22
CA3063872A1 (fr) 2018-11-22
CL2019003270A1 (es) 2020-05-08

Similar Documents

Publication Publication Date Title
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA44861B1 (fr) Modulateurs de la voie de réponse intégrée au stress
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA46018A (fr) Activateurs d'édition du génome
MA41596A (fr) Anticorps anti-tau et leurs utilisations
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA53455B1 (fr) Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr
MA38837B1 (fr) Inhibiteurs de l'autotaxine contenant un noyau à cycle benzyle-amide cyclique hétéroaromatique
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA44917B1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
MX2022008901A (es) Conjugados de proteinas-compuestos antivirales.
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
BR112021014566A2 (pt) Moduladores de gpr35
MX2021006242A (es) Formulaciones de capsula.
EA202090333A1 (ru) Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина
EA202191927A1 (ru) Модуляторы gpr35
MA35894B1 (fr) Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k
MA38451A1 (fr) Benzoimidazol-2-ylpyrimidines modulatrices du récepteur de l'histamine h4
MA38302B1 (fr) Anticorps anti-pdgfr-bêta et leurs utilisations
FR3042191B1 (fr) Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives